SCHEMBL25450894

SCHEMBL25450894

C=C(NCCC)c1ccc(-c2cccc(C(C)(C)C)c2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RXRA P19793 3/20 0.54
▸ RXRB P28702 3/20 0.54
▸ KIF11 P52732 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ CTSS P25774 1/20 0.38
▸ CTSK P43235 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ ERN1 O75460 1/20 0.38
▸ RXRG P48443 1/20 0.37
▸ EGFR P00533 1/20 0.37
▸ DRD2 P14416 1/20 0.36
▸ DRD4 P21917 1/20 0.36
▸ DRD3 P35462 1/20 0.36
▸ KIFC1 Q9BW19 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ ACHE P22303 1/20 0.35
▸ DHODH Q02127 1/20 0.35
▸ HDAC8 Q9BY41 2/20 0.35
▸ HDAC3 O15379 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25450896 0.86 RXRA (0.50) RXRARXRBKIF11KIFC1
SCHEMBL25094351 0.84 RXRA (0.61) RXRARXRBALDH1A1POLBL3MBTL1
SCHEMBL24862600 0.81 HDAC1 (0.47) ALDH1A1POLBL3MBTL1LMNAHDAC8
SCHEMBL27659191 0.72 KIF11 (0.76) RXRARXRBKIF11ALDH1A1CTSS
SCHEMBL13663790 0.70 KMT2A (0.47) ALDH1A1POLBL3MBTL1HDAC3
SCHEMBL13422461 0.70 RXRB (1.00) RXRARXRBKIF11RXRGDHODH
SCHEMBL13524610 0.70 RXRB (0.76) RXRARXRBKIF11RXRGACHE
SCHEMBL25094360 0.70 RXRA (0.57) RXRARXRBALDH1A1EGFRKIFC1
SCHEMBL17105790 0.70 KIF11 (0.68) RXRARXRBKIF11ALDH1A1DHODH
SCHEMBL5547288 0.70 KIF11 (0.72) RXRARXRBKIF11ALDH1A1CTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11648254-B2 Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling KUMQUAT BIOSCIENCES INC. (US) 2023-05-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11648254-B2 Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling KRAS, NRAS, BRAF RXRA 2426/4885RXRB 1594/4885KIF11 3998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback